PATENT CLAIM ANALYSIS

Application Number: 16336363
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "234200"]

Abstract:
The present invention relates to a class of cyano-substituted-heterocycles of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction. (I)

Claim (Index 27):
The method according to  claim 26 , wherein the neurodegenerative disease is selected from Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, ischemia, stroke, dementia with Lewy bodies, frontotemporal dementia; and Parkinson's disease related to mutations in a synuclein, parkin and PINK1, autosomal recessive juvenile Parkinson's disease (AR-JP) where parkin is mutated

Metadata:
- Claim Count in Document: 32.0
- Percentile: 99.0
- Lexical Diversity: 1.32558
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['16070936', '16080506', '15738900', '15894025', '16078518']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8489319376140105
- 35 USC 102 Novelty (BERT): 0.5404571116604671
- Combined Prediction Score: 0.8180844550186562
- Mean Citation Score: 433.761262
- Max Citation Score: 448.00748
- Similarity Product: 205.51921659691337

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test